logo-education
0370 270 6000

already registered?

Please sign in with your existing account details.

need to register?

Register to access exclusive content, sign up to receive our updates and personalise your experience on brownejacobson.com.

Privacy statement - Terms and conditions

Forgotten your password?

Not so simples?

18 May 2012

Compare The Market has failed to seize the rights to the adult domain name comparethemarket.xxx.

In April BGL, the owner of the price comparison brand and a number of registered trade marks, launched a Uniform Domain Name Dispute Resolution Policy complaint with the Czech Arbitration Court, following the .xxx site being registered by a gentleman from Gwent last year.

The panel rejected BGL’s complaint, on the basis that it had failed to show that the .xxx site had been registered in bad faith, as it does not currently resolve to a website.

Trade mark owners should take note, as this decision indicates that they will be required to show clear evidence of bad faith registration (such as offers for sale to the trade mark owner or linking the domain to competitors’ adverts) in order to be successful in a complaint. This will be of particular concern for those linked to an .xxx domain, due to the potential for reputational damage.

Related opinions

Does the move into Step 4 mean the ending of Covid-19 restrictions within schools?

With the Prime Ministers announcement that he intends for Step 4 to begin on 19 July, this will also bring an end to the restrictions currently in place on education settings.

View blog

Advocacy in Action: Female Genital Mutilation Protection Orders (FGMPO)

The issue of Female Genital Mutilation Protection Orders and the importance of education providers to act promptly.

View blog

Responsibilities towards students identifying as non-binary

Our top tips for supporting transgender and non-binary pupils.

View blog

Schools face scrutiny over Covid-19 vaccinations for children

On 4 June, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of the Pfizer/BioNTech Covid-19 vaccine for 12- to 15-year-olds.

View blog

Mailing list sign up

Select which mailings you would like to receive from us.

Sign up